{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:13:42Z","timestamp":1761959622908,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":219,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.lrr.2022.100341","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T12:12:21Z","timestamp":1660047141000},"page":"100341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Exploration of residual disease in stem cell products from mantle cell lymphoma using next-generation sequencing"],"prefix":"10.1016","volume":"18","author":[{"given":"Lea Amalia Lind","family":"Elkj\u00e6r","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oriane","family":"C\u00e9dile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3083-4850","authenticated-orcid":false,"given":"Marcus H\u00f8y","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Boe","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Abildgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Haaber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0411-7594","authenticated-orcid":false,"given":"Charlotte Guldborg","family":"Nyvold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.lrr.2022.100341_bib0001","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3324\/haematol.2017.167627","article-title":"Mantle Cell Lymphoma, Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?","volume":"102","author":"Ferrero","year":"2017","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.lrr.2022.100341_bib0002","doi-asserted-by":"crossref","first-page":"553","DOI":"10.7150\/jca.51959","article-title":"Minimal residual disease and survival outcomes in patients with mantle cell lymphoma: a systematic review and meta-analysis","volume":"12","author":"Zhou","year":"2021","journal-title":"J. Cancer"},{"issue":"12","key":"10.1016\/j.lrr.2022.100341_bib0003","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","article-title":"Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936","volume":"17","author":"van Dongen","year":"2003","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.lrr.2022.100341_bib0004","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.lrr.2022.100341_bib0005","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1038\/s41375-019-0508-7","article-title":"Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS","volume":"33","author":"Scheijen","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.lrr.2022.100341_bib0006","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/bjh.14699","article-title":"Incidence and survival trends in mantle cell lymphoma","volume":"181","author":"Epperla","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.lrr.2022.100341_bib0007","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood.V89.2.724","article-title":"Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting","volume":"89","author":"Corradini","year":"1997","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.lrr.2022.100341_bib0008","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood.V96.3.864","article-title":"Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion","volume":"96","author":"Magni","year":"2000","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.lrr.2022.100341_bib0009","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.clml.2020.09.007","article-title":"Noninvasive monitoring of mantle cell lymphoma by immunoglobulin gene next-generation sequencing in a phase 2 study of sequential chemoradioimmunotherapy followed by autologous stem-cell rescue","volume":"21","author":"Kumar","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"11","key":"10.1016\/j.lrr.2022.100341_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112558","article-title":"Impact of mantle cell lymphoma contamination of autologous stem cell grafts on outcome after high-dose chemotherapy","volume":"13","author":"Roerden","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.lrr.2022.100341_bib0011","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.lrr.2022.100341_bib0012","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00062752-199704060-00011","article-title":"Purging marrow or peripheral blood stem cells for autografting","volume":"4","author":"Hammert","year":"1997","journal-title":"Curr. Opin. Hematol."},{"issue":"10","key":"10.1016\/j.lrr.2022.100341_bib0013","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1093\/annonc\/mdx340","article-title":"Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation","volume":"28","author":"Takamatsu","year":"2017","journal-title":"Annals Oncol."},{"issue":"2","key":"10.1016\/j.lrr.2022.100341_bib0014","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1040-8428(01)00160-3","article-title":"Tumor cell contamination in re-infused stem cell autografts: does it have clinical significance?","volume":"41","author":"Shimoni","year":"2002","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"10.1016\/j.lrr.2022.100341_bib0015","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2022.100341_bib0016","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.exphem.2021.03.005","article-title":"Perspective: sensitive detection of residual lymphoproliferative disease by NGS and clonal rearrangements-how low can you go?","volume":"98","author":"Hansen","year":"2021","journal-title":"Exp. Hematol."},{"issue":"9","key":"10.1016\/j.lrr.2022.100341_bib0017","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood.2019002959","article-title":"Molecular MRD status and outcome after transplantation in NPM1-mutated AML","volume":"135","author":"Dillon","year":"2020","journal-title":"Blood"}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221304892200053X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221304892200053X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:09:39Z","timestamp":1761959379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221304892200053X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":17,"alternative-id":["S221304892200053X"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2022.100341","relation":{},"ISSN":["2213-0489"],"issn-type":[{"type":"print","value":"2213-0489"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploration of residual disease in stem cell products from mantle cell lymphoma using next-generation sequencing","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2022.100341","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100341"}}